Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor | Zendy

Emily Robinson | Zendy; Ursula A. Matulonis | Zendy; Percy Ivy | Zendy; Suzanne Berlin | Zendy; Karin Tyburski | Zendy; Richard T. Penson | Zendy; Benjamin D. Humphreys | Zendy

Open Access

Rapid Development of Hypertension and Proteinuria with Cediranib, an Oral Vascular Endothelial Growth Factor Receptor Inhibitor

Author(s) -

Emily Robinson,

Ursula A. Matulonis,

Percy Ivy,

Suzanne Berlin,

Karin Tyburski,

Richard T. Penson,

Benjamin D. Humphreys

Publication year - 2010

Publication title -

clinical journal of the american society of nephrology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.755

H-Index - 151

eISSN - 1555-905X

pISSN - 1555-9041

DOI - 10.2215/cjn.08111109

Subject(s) - proteinuria , medicine , vascular endothelial growth factor , blood pressure , urology , endocrinology , vegf receptors , kidney

Hypertension and proteinuria are common but poorly understood renal toxicities of vascular endothelial growth factor (VEGF) receptor signaling pathway inhibitors. In this phase II study of cediranib (AZD2171) for recurrent epithelial ovarian cancer, the time course and severity of BP changes and proteinuria were characterized.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research